1,2-二乙基-3-羟基吡啶-4(1H)-酮 | 115900-75-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1,2-二乙基-3-羟基吡啶-4(1H)-酮
• 英文名称: 1,2-diethyl-3-hydroxypyridin-4-one
• 英文别名: 1,2-diethyl-3-hydroxy-4-pyridinone；3-hydroxy-1,2-diethyl-4-pyridinone；1,2-diethyl-3-hydroxypyrid-4-one；CP94；Hdepp；CP-94
• CAS: 115900-75-9
• 化学式: C₉H₁₃NO₂
• mdl: MFCD00869703
• 分子量: 167.208
• InChiKey: XIYFEESCIBNMIC-UHFFFAOYSA-N

物化性质

• 沸点：
  266.3±40.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)
• 溶解度：
  DMF: 30 mg/ml,DMSO: 15 mg/ml,乙醇: 30 mg/ml,PBS (pH 7.2): 10 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  四氯化锡 、 1,2-二乙基-3-羟基吡啶-4(1H)-酮 以 丙酮 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and reactivity of bis-4-pyrone and bis-4-pyridinone dichlorotin(IV) compounds

  摘要：

  A number of tin(IV) complexes, Sn(LL)2X2, have been prepared in which LL is a 4-pyronate or 4-pyridinonate ligand and X is chloride or alkoxide. UV-vis, IR and NMR (H-1, C-13, Sn-119) spectra are reported for these complexes. Reactivities have been established through kinetic studies of nucleophilic substitution in acetonitrile solution. Ligand effects on spectra and reactivity are discussed and compared with those for similar metal(IV) complexes, especially of titanium.

  DOI：

  10.1016/s0277-5387(00)81466-7
• 作为产物：
  描述：

  2-乙基-3-苯基甲氧基吡喃-4-酮 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 6.0h， 生成 1,2-二乙基-3-羟基吡啶-4(1H)-酮
  参考文献：
  名称：

  Burgess, John; Fawcett, John; Patel, Marttand S., Journal of Chemical Research, Miniprint, 1993, # 2, p. 214 - 246

  摘要：

  DOI：

文献信息

• [EN] DESFERRITHIOCIN ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES DE LA DESFERRITHIOCINE ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2015077655A1

  公开（公告）日：2015-05-28

  Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

  铁过载与病理条件相关，如氧化应激、输血性铁过载、地中海贫血、原发性血色病、继发性血色病、糖尿病、肝病、心脏病、癌症、放射损伤、神经或神经退行性疾病、弗里德雷希共济失调（FRDA）、黄斑变性、闭合性头部损伤、肠易激综合征和再灌注损伤。本发明提供使用式（A）和（J）的去铁胱醇类似物的方法和药物组合物，用于治疗和/或预防这些病理条件、金属（如铁、铝、镧系元素或锕系元素（如铀））过载症状和传染病（如疟疾）。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：UNIV OSLO

  公开号：WO2018033719A1

  公开（公告）日：2018-02-22

  The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g. 5 or 6-membered heterocyclic rings (such rings preferably include at least one heteroatom selected from N, S and O, preferably N); wherein any optional substituents may be selected from C1-6 alkyl, C1-6 alkoxy, halogen, nitro, cyano, amine, and substituted amine; each L, which may be the same or different, is a covalent bond or a linker; each W, which may be the same or different, is a non-peptidic hydrophilic group which comprises one or more hydroxy groups; and x is an integer from 1 to 3) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof.

  该发明提供了一种化合物，用于治疗和/或预防人类或非人哺乳动物体内的细菌感染，所述方法包括将该化合物与β-内酰胺类抗生素（可以同时、分开或顺序地）结合给药，其中所述化合物具有一般式I：（I）（其中：Q是一个亲脂性、选择性结合Zn2+离子的基团，包括至少一个，最好是两个或更多（例如2、3或4个），可选择地取代的不饱和杂环环，例如5或6元杂环环（这些环最好包括至少一个从N、S和O中选择的杂原子，最好是N）；其中任何可选择的取代基可以选择自C1-6烷基、C1-6烷氧基、卤素、硝基、氰基、胺和取代胺；每个L，可以相同也可以不同，是一个共价键或一个连接基；每个W，可以相同也可以不同，是一个非肽性亲水基团，包括一个或多个羟基；x是1到3之间的整数）或其立体异构体、药学上可接受的盐或前药。
• Process for producing pyrid-4-ones
  申请人：THE ROYAL FREE HOSPITAL SCHOOL OF MEDICINE

  公开号：EP0335745A1

  公开（公告）日：1989-10-04

  Substituted-3-hydroxy-pyrid-4-ones, derivatives thereof, and salts thereof are produced by reacting subsituted-3-hydroxypyr-4-one with ammonia or a non-sterically hindered primary amine usually in the presence of a solvent such as water. Also disclosed are novel derivatives of 2-ethyl-3-hydroxypyrid-4-one.

  通过将取代的3-羟基吡啶-4-酮与氨或非立体位阻的一级胺反应，通常在水等溶剂的存在下，可以制备取代的3-羟基吡啶-4-酮、其衍生物和盐类。此外，还披露了2-乙基-3-羟基吡啶-4-酮的新衍生物。
• Synthetic methods and in vitro iron binding studies of the novel 1-alkyl-2-ethyl-3-hydroxypyrid-4-one iron chelators
  作者：G.J. Kontoghiorghes、L. Sheppard、J. Barr

  DOI：10.1016/s0020-1693(00)84951-8

  日期：1988.7

  Abstract Three novel iron chelators namely the 1-methyl-, 1-ethyl- and 1-propyl-2-ethyl-3-hydroxypyrid-4-ones were prepared in high yields from ethyl maltol and the related alkylamine in a one step reaction. These chelators formed 3 chelator:1 iron stable, coloured, neutral complexes at physiological pH and mobilise iron from transferrin, ferritin and haemosiderin. The rate of iron mobilisation from

  摘要用一步法从乙基麦芽酚和相关的烷基胺中高收率地制备了三种新型的铁螯合剂，即1-甲基-，1-乙基-和1-丙基-2-乙基-3-羟基吡啶-4-酮。这些螯合剂形成3种螯合剂：1在生理pH值下稳定的，有色的铁中性复合物，并从运铁蛋白，铁蛋白和血铁蛋白中动员铁。这些蛋白质的铁动员速率为转铁蛋白>血铁蛋白>铁蛋白。1-烷基-2-乙基-3-羟基吡啶-4-酮在生理pH下的廉价合成和强铁结合特性需要进一步研究和开发这些化合物及其同系物，以治疗铁超负荷和铁过剩。铁的其他疾病失衡和毒性。
• [EN] INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY<br/>[FR] INHIBITEURS DE MÉTALLO-BÊTA-LACTAMASE (MBL) COMPRENANT UNE FRACTION DE CHÉLATION DU ZINC
  申请人：UNI I OSLO

  公开号：WO2015049546A1

  公开（公告）日：2015-04-09

  The invention provides compounds according to formula I: A - L - B wherein A represents a lipophilic chelating moiety which is selective for Zn2+ ions; L is a covalent bond or a linker; and B is a vector which is either a moiety capable of interacting with one or more biological structures found in a bacterium (preferably in a bacterial cell wall), for example a penicillin-binding protein such as a metallo-β- lactamase or DD-transferase, or a moiety capable of enhancing transport of the compound across a bacterial cell membrane. Such compounds find use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal. In such a method, the compound of formula I may be administered in combination with (either simultaneously, separately, or sequentially) a β-lactam antibiotic.

  该发明提供了符合以下公式I的化合物：A - L - B，其中A代表选择性对Zn2+离子的亲脂螯合基团；L是共价键或连接物；B是矢量，可以是能与细菌中的一个或多个生物结构相互作用的基团（最好是在细菌细胞壁中找到的），例如金黄色葡萄球菌结合蛋白（例如金属β-内酰胺酶或DD-转移酶），或者是能增强化合物穿过细菌细胞膜的基团。这种化合物可用于治疗和/或预防人类或非人哺乳动物的细菌感染的方法。在这种方法中，公式I的化合物可以与（同时、分开或顺序地）β-内酰胺类抗生素一起给予。